Business
Viagra switch to OTC status in the UK
Viagra switch to OTC status in the UK.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8580X N4 Pharma PLC 29 November 2017 \n\n29 November 2017\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\nViagra switch to OTC status in the UK\nN4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, welcomes the announcement of the move to make Viagra 50mg available as an Over The Counter (\"OTC\") product in the UK.\n \nNigel Theobald, CEO of N4 Pharma, commented:\n\"Unlike in the USA, prescription products cannot be advertised directly to consumers in Europe and this move to OTC will make that possible in the UK for sildenafil.\nThe establishment of an OTC market for sildenafil in the UK will bring many opportunities for reformulated products as has happened in other OTC sectors. If this OTC status is widely supported by pharmacists in the UK, our 50mg reformulation of sildenafil will also be able to apply for OTC status.\nThe move is a great endorsement for our decision to reformulate sildenafil.\"\n \n \nEnquiries:\n\n\n\n\nN4 Pharma Plc\nNigel Theobald, CEO,\n\n\n \nVia Alma PR\n\n\n\n\nStockdale Securities\nTom Griffiths\n\n\nTel: +44(0)207 601 6100\n\n\n\n\nBeaufort Securities\nElliot Hance\n\n\nTel: +44(0)207 382 8300\n\n\n\n\nAlma PR\nJosh Royston\nRobyn Fisher\n\n\n \nTel: +44(0)778 090 1979\nTel: +44(0)754 070 6191\n\n\n\n\n \nAbout N4 Pharma\nN4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. \nN4 Pharma's reformulation work falls under two divisions:\n• generic, already commercialised, drugs; and\n• delivery of novel and existing vaccines.\nN4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.\nN4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated ...